IFRX Research and Charts

IFRX - InflaRx NV (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-01-03)

Last 2.41	Change ⇓ -0.09 (-3.60%)	Volume 227,800
	Open 2.52	High 2.52	Low 2.28

8EMA (Daily) 2.47	40EMA (Daily) 2.23	50EMA (Daily) 2.15	STO (Daily) 70.976	MACD Hist (Daily) -0.025
8EMA (Weekly) 2.285	40EMA (Weekly) 1.88	50EMA (Weekly) 1.90	STO (Weekly) 74.014	MACD Hist (Weekly) 0.168


Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.